Literature DB >> 21558757

2-Aminophenoxazine-3-one and 2-amino-4,4α-dihydro-4α,7-dimethyl-3H-phenoxazine-3-one cause cellular apoptosis by reducing higher intracellular pH in cancer cells.

Xiao-Fang Che1, Chun-Lei Zheng, Shin-Ichi Akiyama, Akio Tomoda.   

Abstract

We examined intracellular pH (pHi) of ten cancer cell lines derived from different organs and two normal cell lines including human embryonic lung fibroblast cells (HEL) and human umbilical vein endothelial cells (HUVEC) in vitro, and found that pHi of most of these cancer cells was evidently higher (pH 7.5 to 7.7) than that of normal cells (7.32 and 7.44 for HEL and HUVEC, respectively) and that of primary leukemic cells and erythrocytes hitherto reported (≤7.2). Higher pHi in these cancer cells could be related to the Warburg effect in cancer cells with enhanced glycolytic metabolism. Since reversal of the Warburg effect may perturb intracellular homeostasis in cancer cells, we looked for compounds that cause extensive reduction of pHi, a major regulator of the glycolytic pathway and its associated metabolic pathway. We found that phenoxazine compounds, 2-aminophenoxazine-3-one (Phx-3) and 2-amino-4,4α-dihydro-4α,7-dimethyl-3H-phenoxazine-3-one (Phx-1) caused a rapid and drastic dose-dependent decrease of pHi in ten different cancer cells within 30 min, though the extent of the decrease of pHi was significantly larger for Phx-3pHi = 0.6 pH units or more for 100 µM Phx-3) than for Phx-1 (ΔpHi = 0.1 pH units or more for 100 µM Phx-1). This rapid and drastic decrease of pHi in a variety of cancer cells caused by Phx-3 and Phx-1 possibly perturbed their intracellular homeostasis, and extensively affected the subsequent cell death, because these phenoxazines exerted dose-dependent proapoptotic and cytotoxic effects on these cells during 72 h incubation, confirming a causal relationship between ΔpHi and cytotoxic effects due to Phx-3 and Phx-1. Phx-3 and Phx-1 also reduced pHi of normal cells including HEL and HUVEC, although they exerted less proapoptotic and cytotoxic effects on these cells than on cancer cells. Drugs such as Phx-3 and Phx-1 that reduce pHi and thereby induce cellular apoptosis might serve as benevolent anticancer drugs.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21558757      PMCID: PMC3149379          DOI: 10.2183/pjab.87.199

Source DB:  PubMed          Journal:  Proc Jpn Acad Ser B Phys Biol Sci        ISSN: 0386-2208            Impact factor:   3.493


  57 in total

1.  Changes in intramitochondrial and cytosolic pH: early events that modulate caspase activation during apoptosis.

Authors:  S Matsuyama; J Llopis; Q L Deveraux; R Y Tsien; J C Reed
Journal:  Nat Cell Biol       Date:  2000-06       Impact factor: 28.824

2.  On the origin of cancer cells.

Authors:  O WARBURG
Journal:  Science       Date:  1956-02-24       Impact factor: 47.728

3.  Identification of N10-substituted phenoxazines as potent and specific inhibitors of Akt signaling.

Authors:  Kuntebommanahalli N Thimmaiah; John B Easton; Glen S Germain; Christopher L Morton; Shantaram Kamath; John K Buolamwini; Peter J Houghton
Journal:  J Biol Chem       Date:  2005-07-11       Impact factor: 5.157

4.  A role of phosphofructokinase in pH-dependent regulation of glycolysis.

Authors:  M Ui
Journal:  Biochim Biophys Acta       Date:  1966-08-24

5.  Antitumor effects of a novel phenoxazine derivative on human leukemia cell lines in vitro and in vivo.

Authors:  T Shimamoto; A Tomoda; R Ishida; K Ohyashiki
Journal:  Clin Cancer Res       Date:  2001-03       Impact factor: 12.531

6.  Acid pH in tumors and its potential for therapeutic exploitation.

Authors:  I F Tannock; D Rotin
Journal:  Cancer Res       Date:  1989-08-15       Impact factor: 12.701

7.  Antitumor activity of a phenoxazine compound, 2-amino-4,4alpha-dihydro-4alpha,7-dimethyl-3H-phenoxazine-3-one against human B cell and T cell lymphoblastoid cell lines: induction of mixed types of cell death, apoptosis, and necrosis.

Authors:  J Koshibu-Koizumi; M Akazawa; T Iwamoto; M Takasaki; F Mizuno; R Kobayashi; A Abe; A Tomoda; M Hamatake; R Ishida
Journal:  J Cancer Res Clin Oncol       Date:  2002-06-18       Impact factor: 4.553

8.  Suppression of the proliferation of cancer cell lines, KB-3-1 and K562 cells preceded by a decrease in intracellular pH caused by phenoxazine derivatives.

Authors:  Xiao-Fang Che; Shin-ichi Akiyama; Akio Tomoda
Journal:  Oncol Rep       Date:  2008-05       Impact factor: 3.906

Review 9.  Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review.

Authors:  P Vaupel; F Kallinowski; P Okunieff
Journal:  Cancer Res       Date:  1989-12-01       Impact factor: 12.701

10.  The phenoxazine derivative Phx-1 suppresses IgE-mediated degranulation in rat basophilic leukemia RBL-2H3 cells.

Authors:  Eisuke Enoki; Kiyonao Sada; Xiujuan Qu; Shinkou Kyo; S M Shahjahan Miah; Tomoko Hatani; Akio Tomoda; Hirohei Yamamura
Journal:  J Pharmacol Sci       Date:  2004-03       Impact factor: 3.337

View more
  10 in total

1.  Synthesis and properties of peptide nucleic acid labeled at the N-terminus with HiLyte Fluor 488 fluorescent dye.

Authors:  Dziyana Hnedzko; Dennis W McGee; Eriks Rozners
Journal:  Bioorg Med Chem       Date:  2016-07-06       Impact factor: 3.641

2.  Glycolysis, tumor metabolism, cancer growth and dissemination. A new pH-based etiopathogenic perspective and therapeutic approach to an old cancer question.

Authors:  Khalid O Alfarouk; Daniel Verduzco; Cyril Rauch; Abdel Khalig Muddathir; H H Bashir Adil; Gamal O Elhassan; Muntaser E Ibrahim; Julian David Polo Orozco; Rosa Angela Cardone; Stephan J Reshkin; Salvador Harguindey
Journal:  Oncoscience       Date:  2014-12-18

Review 3.  Microenvironmental acidosis in carcinogenesis and metastases: new strategies in prevention and therapy.

Authors:  Stefano Fais; Giulietta Venturi; Bob Gatenby
Journal:  Cancer Metastasis Rev       Date:  2014-12       Impact factor: 9.264

Review 4.  (Patho-)Physiology of Na+/H+ Exchangers (NHEs) in the Digestive System.

Authors:  Li Cao; Zhenglin Yuan; Mei Liu; Christian Stock
Journal:  Front Physiol       Date:  2020-01-15       Impact factor: 4.566

Review 5.  Pharmacological Activities of Aminophenoxazinones.

Authors:  Jesús G Zorrilla; Carlos Rial; Daniel Cabrera; José M G Molinillo; Rosa M Varela; Francisco A Macías
Journal:  Molecules       Date:  2021-06-07       Impact factor: 4.411

Review 6.  Prevention of carcinogenesis and development of gastric and colon cancers by 2-aminophenoxazine-3-one (Phx-3): direct and indirect anti-cancer activity of Phx-3.

Authors:  Akio Tomoda; Keisuke Miyazawa; Takafumi Tabuchi
Journal:  Int J Mol Sci       Date:  2013-08-28       Impact factor: 5.923

Review 7.  Cariporide and other new and powerful NHE1 inhibitors as potentially selective anticancer drugs--an integral molecular/biochemical/metabolic/clinical approach after one hundred years of cancer research.

Authors:  Salvador Harguindey; Jose Luis Arranz; Julian David Polo Orozco; Cyril Rauch; Stefano Fais; Rosa Angela Cardone; Stephan J Reshkin
Journal:  J Transl Med       Date:  2013-11-06       Impact factor: 5.531

8.  Neutral metalloaminopeptidases APN and MetAP2 as newly discovered anticancer molecular targets of actinomycin D and its simple analogs.

Authors:  Ewelina Węglarz-Tomczak; Michał Talma; Mirosław Giurg; Hans V Westerhoff; Robert Janowski; Artur Mucha
Journal:  Oncotarget       Date:  2018-06-29

Review 9.  A New and Integral Approach to the Etiopathogenesis and Treatment of Breast Cancer Based upon Its Hydrogen Ion Dynamics.

Authors:  Salvador Harguindey; Khalid Alfarouk; Julián Polo Orozco; Kevin Hardonniere; Daniel Stanciu; Stefano Fais; Jesús Devesa
Journal:  Int J Mol Sci       Date:  2020-02-07       Impact factor: 5.923

Review 10.  Towards an Integral Therapeutic Protocol for Breast Cancer Based upon the New H+-Centered Anticancer Paradigm of the Late Post-Warburg Era.

Authors:  Salvador Harguindey; Khalid Alfarouk; Julián Polo Orozco; Stefano Fais; Jesús Devesa
Journal:  Int J Mol Sci       Date:  2020-10-10       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.